Investigated people are healthy adults.
Conditions
Interventions
Trade Name: Nitroglycerin 0.5 mg resoriblette
Product Name: Nitroglycerin
Pharmaceutical Form: Sublingual tablet
Sponsors
Oulu Functional NeuroImaging, MRC/MIPT, Oulu University Hospital
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Subjects need to be healthy controls without chronic illnesses, 18-70 years of age, no continuous medications (not including conrtaceptives and thyroxin). Are the trial subjects under 18? no Number of subjects for this age range: F.1.2 Adults (18-64 years) yes F.1.2.1 Number of subjects for this age range 15 F.1.3 Elderly (>=65 years) yes F.1.3.1 Number of subjects for this age range 10
Exclusion criteria
Exclusion criteria: chronic illness, all MRI contraindications, tobacco smoking, pregnancy, breast feeding, drug abuse
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Main Objective: To test EAC treatment effect in healthy controls for augmenting glymphatic clearance.;Secondary Objective: Investigate treatment safety.;Primary end point(s): Brain imaging and laboratory changes induced by the treatment.;Timepoint(s) of evaluation of this end point: Immediate treatment after 1st given EAC & nitroglycerin treatment. | — |
Secondary
| Measure | Time frame |
|---|---|
| Secondary end point(s): Physiological changes during treatment.;Timepoint(s) of evaluation of this end point: During EAC treatment. | — |
Countries
Finland
Outcome results
None listed